IP Library Granted Patent US 8,440,400
Granted Patent B2
US 8,440,400 · App. 12/996,108 · Granted May 14, 2013

Process for amplifying DNA in cells

Inventors: Takeshi Murakami (Minamiashigara, JP); Naomi Sumida (Odawara, JP); Koji Yanai (Minamiashigara, JP)
Assignee: Meiji Seika Pharma Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,440,400
App. No.
12/996,108
Granted
May 14, 2013
Kind
B2
Abstract

The present invention relates to a process for efficiently amplifying a giant DNA. More particularly, the present invention relates to a process for amplifying DNA in a cell, comprising amplifying the DNA as the target of amplification in the presence of DNAs selected from the following (i), (ii) and (iii): (i) DNA encoding a protein selected from the following 1), 2) and 3): 1) a protein consisting of the amino acid sequence of SEQ ID NO: 1, 2) a protein comprising an amino acid sequence which has a deletion, substitution, insertion or addition of one or more amino acids in the amino acid sequence of SEQ ID NO: 1, and 3) a protein comprising an amino acid sequence which has an identity of 90% or more to the amino acid sequence of SEQ ID NO: 1, (ii) DNA consisting of the nucleotide sequence of SEQ ID NO: 2, and (iii) DNA hybridizing to the nucleotide sequence of SEQ ID NO: 2 under stringent conditions.

Claims (26)

1. A process for amplifying DNA, comprising:

preparing a recombinant cell comprising:

any one polynucleotide selected from the group consisting of the following (A) to (D), and

a DNA unit disposed in a genome of the recombinant cell, wherein said DNA unit comprises at least first DNA fragment selected from the group consisting of the following (E) to (G), a target gene, and a second DNA fragment selected from the group consisting of (H) to (J),

and wherein said target gene or polynucleotide is exogenous to said recombinant cell;

(A) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 1,

(B) a polynucleotide encoding a protein which consists of an amino acid sequence having an identity of 90% or more to the amino acid sequence of SEQ ID NO: 1,

(C) a polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2, and

(D) a polynucleotide which hybridizes to the polynucleotide consisting of the nucleotide sequence of SEQ ID NO: 2 under stringent conditions,

(E) DNA consisting of the nucleotide sequence of SEQ ID NO: 3,

(F) DNA hybridizing to the DNA consisting of the nucleotide sequence of SEQ ID NO: 3 under stringent conditions, and

(G) DNA having an identity of 90% of more to the nucleotide sequence of SEQ ID NO: 3,

(H) DNA represented by the nucleotide of SEQ ID NO: 4,

(I) DNA hybridizing to DNA consisting of the nucleotide sequence of SEQ ID NO: 4 under stringent conditions, and

(J) DNA having an identity of 90% of more to the nucleotide sequence of SEQ ID NO: 4; and

culturing said recombinant cell under conditions for causing gene amplification to amplify said DNA unit.

2. The process according to claim 1 , wherein said DNA unit has a size of 22 to 154 kb.

3. The process according to claim 1 , wherein said DNA unit comprises, in order from the 5′-terminal, the first DNA fragment, the target gene, and the second DNA fragment.

4. The process according to claim 1 , wherein said target gene consists of an antibiotic biosynthetic gene cluster.

5. The process according to claim 1 , wherein said DNA unit further comprises a drug-resistance gene.

6. The process according to claim 1 , wherein said polynucleotide is DNA and is disposed in the genome of said recombinant cell.

7. The process according to claim 1 , wherein said host is an antibiotic-producing strain.

8. A recombinant cell produced by the method of claim 1 , having multiple copies of said DNA unit introduced into the genome of the recombinant cell.

9. The recombinant cell according to claim 8 , wherein said target gene is exogenous to the host.

10. The recombinant cell according to claim 8 , wherein said polynucleotide is exogenous to the host, and said target gene is endogenous or exogenous to the host.

11. The recombinant cell according to claim 10 , wherein said first DNA fragment and said second DNA fragment are exogenous to the host.

Assignments (2)
CHANGE OF NAME Recorded Apr 4, 2013
From: MEIJI SEIKA KAISHA, LTD.
To: MEIJI SEIKA PHARMA CO., LTD.
Reel/Frame 030148/0664 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2010
From: MURAKAMI, TAKESHI; SUMIDA, NAOMI; YANAI, KOJI
To: MEIJI SEIKA KAISHA, LTD.
Reel/Frame 025447/0750 →
Priority Claims (1)
JP 2008-147927 · Jun 5, 2008 · national
Continuity (1)
Related Publication 20110171692A1 · Jul 14, 2011